User profiles for David L. Bigam

David Bigam

Verified email at ualberta.ca
Cited by 14552

Gastric adenocarcinoma: review and considerations for future directions

BJ Dicken, DL Bigam, C Cass, JR Mackey… - Annals of …, 2005 - journals.lww.com
Objective: This update reviews the epidemiology and surgical management, and the
controversies of gastric adenocarcinoma. We provide the relevance of outcome data to surgical …

[PDF][PDF] Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database

C Toso, S Asthana, DL Bigam, AMJ Shapiro… - …, 2009 - Wiley Online Library
The current model of liver graft allocation in place in the United States favors transplantation
of patients with small hepatocellular carcinomas (HCCs) within the Milan criteria (a single …

Sirolimus‐based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma

C Toso, S Merani, DL Bigam, AMJ Shapiro… - …, 2010 - Wiley Online Library
Liver transplantation is an important treatment option for selected patients with nonresectable
hepatocellular carcinoma (HCC). Several reports have suggested a lower risk of …

[PDF][PDF] Sirolimus‐based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma

…, AMJ Shapiro, VG Bain, DL Bigam - Liver …, 2004 - Wiley Online Library
An increasing number of patients with hepatocellular carcinoma (HCC) are undergoing
evaluation for listing for liver transplantation. Criteria for selection require ongoing review for …

[PDF][PDF] Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma

C Toso, J Trotter, A Wei, DL Bigam, S Shah… - Liver …, 2008 - Wiley Online Library
Criteria for the selection of candidates for liver transplantation in the presence of
hepatocellular carcinoma (HCC) should accurately predict posttransplant recurrence while not …

De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects

C Toso, GA Meeberg, DL Bigam, J Oberholzer… - …, 2007 - journals.lww.com
Background. We report long-term outcomes and side effects after transplantation for hepatocellular
carcinoma (HCC) using de novo, sirolimus-based immunosuppression (IS). Methods. …

The impact of muscle and adipose tissue on long-term survival in patients with stage I to III colorectal cancer

JJ Hopkins, RL Reif, DL Bigam… - Diseases of the Colon …, 2019 - journals.lww.com
BACKGROUND: Computed tomography-derived body composition parameters are emerging
prognostic factors in colorectal cancer. OBJECTIVE: This study aimed to determine the …

[HTML][HTML] Portal vein thrombosis is a potentially preventable complication in clinical islet transplantation

…, T Kin, S Kashkoush, B Gala-Lopez, DL Bigam… - American journal of …, 2011 - Elsevier
Percutaneous transhepatic portal access avoids surgery but is rarely associated with bleeding
or portal venous thrombosis (PVT). We herein report our large, single-center experience …

Strategic opportunities in clinical islet transplantation

…, JRT Lakey, BW Paty, PA Senior, DL Bigam… - …, 2005 - journals.lww.com
More than 471 patients with type 1 diabetes have received islet transplants at 43 institutions
worldwide in the past 5 years. High rates of insulin independence have been observed at 1 …

Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects

…, JRT Lakey, MC McCarthy, BW Paty, DL Bigam… - Radiology, 2003 - pubs.rsna.org
PURPOSE: To report our experience with percutaneous transhepatic pancreatic islet cell
transplantation in patients with type 1 diabetes mellitus. MATERIALS AND METHODS: …